Dual CGRP therapy — combining a monoclonal antibody with a small-molecule antagonist — reduced chronic migraine headache severity by 20% versus 10% with single-agent therapy, with no additional safety concerns.
20% vs 10% severity reduction (p=0.039)Dual CGRP therapy produced significantly greater headache severity reduction than mono therapy, with some patients experiencing up to 14 fewer headache days per month.
What the researchers found
Among 90 chronic migraine patients (27 on dual CGRP therapy, 63 on mono therapy):
- Dual therapy reduced headache severity by 20% vs 10% with mono therapy (p = 0.039)
- Dual therapy patients averaged 4 fewer headache days, with some experiencing up to 14 fewer days, though this did not reach statistical significance (p = 0.112)
- No significant differences in other migraine-associated symptoms (nausea, photophobia, etc.)
- Adverse events were mild in both groups with no serious events or discontinuations
- Both treatment approaches used CGRP ligand-targeting antibodies combined with receptor-targeting small molecules for synergistic blockade
Why it matters
A significant proportion of chronic migraine patients have an inadequate response to single CGRP drugs. This is the first real-world evidence that combining two different types of CGRP-targeting medications — attacking the peptide from two angles simultaneously — can provide additional benefit without added safety risks. This dual approach could change treatment strategies for the most difficult-to-treat migraine patients.
How the study worked
Retrospective matched cohort study at a single US neurological center. 90 chronic migraine patients treated with CGRP inhibitors between May 2018 and February 2024 were analyzed. 27 patients on dual therapy (L-mAb + SMA) were matched by age and gender with 63 mono-therapy patients. Outcomes including headache frequency, duration, severity, and symptoms were compared at baseline and 3 months post-treatment.
What this study cannot tell us
Small sample size (90 patients, only 27 on dual therapy) at a single center limits generalizability. Retrospective design introduces selection and confounding bias. The 3-month follow-up is relatively short. The headache frequency reduction, while clinically meaningful (up to 14 fewer days), did not reach statistical significance. Newer CGRP agents were not included. The predominantly female patient population may not represent all migraine patients.
How to read the evidence
This is a small retrospective matched cohort study from a single center. While it provides the first real-world evidence for dual CGRP therapy, the study design and small sample size mean the findings should be viewed as preliminary and hypothesis-generating.
When this study was published
Published in 2026 with data through February 2024, this addresses a cutting-edge treatment question as clinicians increasingly explore combination CGRP strategies for refractory migraine.
The bigger picture
CGRP-targeting drugs have transformed migraine treatment, but many patients still have incomplete responses. The concept of dual CGRP blockade — combining an antibody against the CGRP peptide molecule with a small molecule blocking the CGRP receptor — represents a mechanistically logical next step. If confirmed in larger trials, this approach could become standard care for refractory chronic migraine, similar to how combination therapy has become the norm in other chronic conditions.
Questions still open
- Would a larger randomized controlled trial confirm the headache frequency reduction seen with dual CGRP therapy?
- Which specific combinations of CGRP antibodies and small molecules are most effective together?
- Are there long-term safety concerns with blocking the CGRP pathway through two mechanisms simultaneously?
Common questions
Why would combining two CGRP drugs work better than one?
Is dual CGRP therapy safe?
Read the original research
Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.
Pain physician, 29(1), 75-82
Citation
Lee, Ho Hyun; Cheung, Anita J; Lee, Anson Y; Jahansooz, Julia R; Weldon, Edward J; Ishikawa, Kyle M; Yoshioka, Reyn; Woo, Man Ian; Liquard, Lana; Kim, Eonjung Angeline; Carrazana, Enrique; Liow, Kore K. (2026). Real-World Insights into Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Chronic Migraine: A Retrospective Review.. Pain physician, 29(1), 75-82.